Unraveling the paradoxical link between obesity and heart failure: The role of adipocytokines

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 4, 2009, Pages 337-340

  Patel, Jeetesh V ^a   Tracey, Inessa ^a   Hughes, Elizabeth A ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; MESSENGER RNA;

CARDIOVASCULAR RISK; DISEASE ASSOCIATION; EDITORIAL; ENERGY BALANCE; GENETIC VARIABILITY; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HORMONE METABOLISM; HUMAN; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; ANIMAL; METABOLISM; RISK FACTOR;

ADIPOKINES; ADIPONECTIN; ANIMALS; HEART FAILURE; HUMANS; LEPTIN; OBESITY; RISK FACTORS;

EID: 67650330454     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.12     Document Type: Editorial

References (62)

1. Hobbs FDR, Kenkre J, Roalfe AK, Davis RC, Hare R, Davies MK. Impact of heart failure and left ventricular systolic dysfunction on quality of life. Eur. Heart J. 23, 1867-1876 (2002).
2. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88, 107-115 (1993).
3. McMurray JJ, Stewart S. Epidemiology, aetiology and prognosis of heart failure. Heart 83, 596-602 (2000).
4. Spencer F, Meyer T, Goldberg RJ et al. Twenty year trends (1975-1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective. J. Am. Coll. Cardiol. 34, 1378-1387 (1999).
5. Nicod P, Gilpin E, Dittrich H et al. Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction. Am. J. Cardiol. 61, 1165-71 (1988).
6. Emanuelsson H, Karlson W, Herlitz J. Characteristics and prognosis of patients with acute myocardial infarction in relation to occurrence of congestive heart failure. Eur. Heart J. 15, 761-768 (1994).
7. Opie LH. The metabolic vicious cycle in heart failure. Lancet 364, 1733-1734 (2004).
8. Kannel WB, LeBauer EJ, Dawber TR, McNamara PM. Relation of body weight to development of coronary heart disease. The Framingham Study. Circulation 35, 734-744 (1967).
9. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am. J. Med. Sci. 321, 225-236 (2001).
10. Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N. Engl. J. Med. 347(5), 305-13 2002.
11. Stamler J. Epidemiologic findings on body mass and blood pressure in adults. Ann. Epidemiol. 1, 347-362 (1991).
12. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care 2, 120-126 (1979).
13. Considine RV, Subha MK, Heiman ML et al. Serum immunoreactive leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334, 292-295 (1996).
14. Tong J, Fujimoto WY, Kahn SE et al. Insulin, C-peptide, and leptin concentrations predict increased visceral adiposity at 5- and 10- year follow-ups in nondiabetic Japanese Americans. Diabetes 54, 985-990 (2004).
15. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257, 79-83 (1999).
16. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler. Thromb. Vasc. Biol. 16, 368-374 (1996).
17. Winkler G, Cseh K, Baranyi E et al. Tumor necrosis factor system in insulin resistance in gestational diabetes. Diabetes Res. Clin. Prac. 56, 93-99 (2002).
18. Chu N-F, Spiegelmann D, Hotamisligil GS, Rifai N, Stampfer M, Rimm EB. Plasma insulin, leptin, and soluble TNF receptor levels in relation to obesity-related atherogenic anf thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 157, 495-503 (2001).
19. Chu NF, Shen MH, Wu DM, Shieh SM. Plasma TNF-R1 and insulin concentrations in relation to leptin levels among normal and overweight children. Clin. Chem. 35, 287-92 (2002).
20. Neely JR, Grotyohann LW. Role of glycolytically derived protons and lactate and damage to the myocardium. Dissociation of adenosine triphosphate levels and recovery function of reperfused ischaemic hearts. Circ. Res. 55, 816-824 (1984).
21. Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischaemic heart disease: the clinician's perspective. Heart Fail. Rev. 7, 187-203 (2002).
22. Banks WA. The many lives of leptin. Peptides 25, 331-338 (2004).
23. Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Leptin as a cardiac hypertrophic factor: a potential target for therapeutics. Trends Cardiovasc. Med. 17, 206-211 (2007).
24. Tartaglia LA, Dembski M, Weng X et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83, 1263-1271 (1995).
25. Keiffer TJ, Habener JF. The adipoinsular axis: effects of leptin on pancreatic β-cells. Am. J. Physiol. Endocrinol. Metab. 278, E1-E14 (2000).
26. Giandomenico G, Dellas C, Czekay RP, Koschnick S, Loskutoff DJ. The leptin receptor system of human platelets. J. Thiomb. Haemost. 3, 1042-1049 (2005).
27. Quilliot D, Böhme P, Zannad F, Ziegler O. Sympathetic-leptin relationship in obesity: effect of weight loss. Metabolism 57, 555-562 (2008).
28. Doehner W, Pflaum CD, Rauchhaus M et al. Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur. J. Endocrinol. 145, 727-735 (2001).
29. Kolaczynski JW, Nyce MR, Considine RV et al. Acute and chronic effects of insulin on leptin production in humans: studies in vivo and in vitro. Diabetes 45(5), 699-701 (1996).
30. Perego L, Pizzocri P, Corradi D et al. Circulating leptin correlates with left ventricular mass in morbid (grade III) obesity before and after weight loss induced by bariatric surgery: a potential role for leptin in mediating human left ventricular hypertrophy. J. Clin. Endocrinol. Metab. 90, 4087-4093 (2005).
31. Patel JV, Sosin M, Lim HS et al. Raised, leptin concentrations among South Asian patients with chronic heart failure. Int. J. Cardiol. 122, 34-40 (2007).
32. Schulze PC, Kratzsch J, Linke A et al. Elevated serum levels of leptin and soluble leptin receptors in patients with advanced chronic heart failure. Eur. J. Heart Fail. 5, 33-40 (2003).
33. Ferrari R, Bachetti T, Confortini R et al. Circulation. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92, 1479-1486 (1995).
34. Takahashi N, Waelput W, Guisez Y. Leptin is an endogenous protective protein against the toxicity exerted by tumour necrosis factor. J. Exp. Med. 189, 207-212 (1999).
35. Szczepaniak LS, Dobbins RL, Metzger GJ et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn. Reson. Med. 49, 417-423 (2003).
36. Barouch LA, Gao D, Chen L et al. Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. Circ. Res. 98, 119-124 (2006).
37. McGaffin KR, Sun CK, Rager JJ et al. Leptin signalling reduces the severity of cardiac dysfunction and remodelling after chronic ischaemic injury. Cardiovasc. Res. 77, 4-5 (2008).
38. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and Type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86, 1930-1935 (2001).
39. Hara K, Yamauchi T, Imai Y et al. Reduced adiponectin level is associated with severity of coronary artery disease. Int. Heart J. 48, 149-153(2007).
40. Patel JV, Lim HS, Hughes EA, Lip GY. Adiponectin and hypertension: a putative link between adipocyte function and atherosclerotic risk? J. Hum. Hypertens. 21, 1-4 (2007).
41. von Eynatten M, Schneider JG, Humpert PM et al. Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men. J. Am. Coll. Cardiol. 47(10), 2124-2126 (2006).
42. Pischon T, Girman CJ, Hotamisligil GS et al. Plasma adiponectin levels and risk of mycardila infarction in men. JAMA 291, 1730-1737 (2004).
43. Schulze MB, Shai I, Rimm EB et al. Adiponectin and future coronary heart disease events among men with Type 2 diabetes. Diabetes 54, 534-539 (2005).
44. Shibata R, Izumiya Y, Sato K et al. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J. Mol. Cell Cardiol. 42, 1065-1074 (2007).
45. Shibata R, Ouchi N, Ito M et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 10, 1384-1389 (2004).
46. Liao Y, Takashima S, Maeda N et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc. Res. 67, 705-713 (2005).
47. Iacobellis G, Petrone A, Leonetti F, Buzzetti R, Left ventricular mass and +276 G/G single-nucleotide polymorphism of the adiponectin gene in uncomplicated obesity. Obesity 14, 368-372 (2006).
48. Fineiro R, Iglesias MJ, Gallego R et al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett. 579, 5163-5169 (2005).
49. Wolf G. Adiponectin: a regulator of energy homeostasis. Nutr. Rev. 61, 290-292 (2003).
50. Palanivel R, Fang X, Park M. Globular and full-length adiponectin mediate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocytes. Cardiovasc. Res. 75, 148-157 (2007).
51. Lavie CJ, Messerli FH. Cardiovascular adaptation to obesity and hypertension. Chest 90, 275-279 (1986).
52. Manson JE, Colditz GA, Stampfer MJ et al. A prospective study of obesity and risk of coronary heart disease in women. N. Engl. J. Med. 322, 882-889 (1990)
53. Garavaglia GE, Messerli FH, Nunez BD, Schmieder RE, Grossman E. Myocardial contractility and left ventricular function in obese patients with essential hypertension. Am. J. Cardiol. 62, 594-597 (1988).
54. Nakamura T, Funayama H, Kubo N et al. Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure. Circ. J. 70, 1557-1562 (2006).
55. Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body mass index and mortality in patients with chronic heart failure. Circulation 112, 1756-1762 (2005).
56. Tamura T, Furukawa Y, Taniguchi R et al. Serum adiponectin as an independent predictor of mortality in patients with congestive heart failure. Circ. J. 71, 623-630 (2007).
57. Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am. J. Cardiol. 91, 891-894 (2003).
58. Horwich TB, Fonarow GC, Hamilton MA et al. The relationship between obesity and mortality in patients with heart failure. J. Am. Coll. Cardiol. 38, 789-795 (2001).
59. Mosterd A, Cost B, Hoes AW et al. The prognosis of heart failure in the general population: the Rotterdam Study. Eur. Heart J. 22, 1318-1327 (2001).
60. Lim HS, Tayebjee MH, Tan KT, Patel JV, Macfadyen RJ, Lip GYH. Severity differences and relation to coronary artery disease serum adiponectin in coronary heart disease. Heart 91, 1605-1606 (2005).
61. Iwashima Y, Katsuya T, Ishikawa K et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43, 1318-1323 (2003).
62. Lieb W, Sullivan LM, Harris TB et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease and total mortality in the elderly. Diabetes Care (2008) (In Press).